Phenprocoumon
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (RS)-4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a699003 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | hepatic to inactive metabolites |
| Half-life | 5 to 6 days |
| Identifiers | |
| CAS number | 435-97-2 |
| ATC code | B01AA04 |
| PubChem | CID 9908 |
| DrugBank | APRD00228 |
| ChemSpider | 10441592 |
| UNII | Q08SIO485D |
| KEGG | D05457 |
| ChEBI | CHEBI:50438 |
| ChEMBL | CHEMBL1465 |
| Chemical data | |
| Formula | C18H16O3 |
| Mol. mass | 280.318 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is an anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism).
Phenprocoumon is a 4-hydroxycoumarin and inhibits inhibits vitamin K epoxide reductase.[1]
[edit] References
- ^ Phenprocoumon at PharmGKB
[edit] External links
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |